Travere Therapeutics' Interest & Investment Income fell 14.65% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year decrease of 34.24%. This contributed to the annual value of $17.8 million for FY2024, which is 18.15% down from last year.
Per Travere Therapeutics' latest filing, its Interest & Investment Income stood at $3.0 million for Q3 2025, which was down 7.30% from $3.3 million recorded in Q2 2025.
Travere Therapeutics' 5-year Interest & Investment Income high stood at $14.4 million for Q4 2022, and its period low was -$5.3 million during Q1 2021.
Its 3-year average for Interest & Investment Income is $4.5 million, with a median of $3.8 million in 2025.
In the last 5 years, Travere Therapeutics' Interest & Investment Income surged by 413.06% in 2022 and then crashed by 50.44% in 2023.
Travere Therapeutics' Interest & Investment Income (Quarterly) stood at -$4.6 million in 2021, then skyrocketed by 413.06% to $14.4 million in 2022, then plummeted by 50.44% to $7.2 million in 2023, then crashed by 46.94% to $3.8 million in 2024, then declined by 14.65% to $3.0 million in 2025.
Its last three reported values are $3.0 million in Q3 2025, $3.3 million for Q2 2025, and $3.8 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value